Inger Rydin is appointed interim COO and takes office immediately

Integrum AB (publ), the medical technology company that improves the lives of amputees, announces that Inger Rydin has been appointed interim COO and will be responsible for operations at the office in Mölndal, Sweden. Inger, who served as interim COO at Integrum from 2021 to 2023, will be part of the management team. She takes office immediately.

“Inger Rydin is a senior and experienced leader who knows Integrum well. She is warmly welcomed to the management team. I look forward to working with Inger to create a value-driven organization that primarily focuses on the growth opportunities in the US,” comments Scott Flora, CEO of Integrum.

Inger Rydin served as acting COO at Integrum from 2021 to 2023. She built a career in various leading strategic and operational positions at Essity, Mölnlycke Healthcare and Coloplast. Inger has also been CEO of fast-growing owner-managed companies and has served on the boards of companies listed in Oslo and Stockholm.

“Integrum is on an exciting commercial journey, and I’m happy to join and contribute with my global experience,” comments Inger Rydin, COO of Integrum.

For more information, please contact Scott Flora, CEO, by email scott.flora@integrum.se

Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.

About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.